AS
NVCR icon

Altshuler Shaham’s NovoCure NVCR Stock Holding History

Altshuler Shaham’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-743
Closed -$98K – 696
2021
Q1 		$98K Sell
743
-2,949
-80% -$466K ﹤0.01% 223
2020
Q4 		$639K Buy
+3,692
New +$505K 0.01% 89
2020
Q1 		– Sell
-349
Closed -$29K – 568
2019
Q4 		$29K Buy
349
+18
+5% +$1.45K ﹤0.01% 224
2019
Q3 		$24K Buy
331
+145
+78% +$11.6K ﹤0.01% 225
2019
Q2 		$12K Sell
186
-206
-53% -$10.4K ﹤0.01% 264
2019
Q1 		$19K Buy
+392
New +$18.9K ﹤0.01% 189
2018
Q4 		– Sell
-155
Closed -$8K – 288
2018
Q3 		$8K Buy
+155
New +$6.17K ﹤0.01% 185

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altshuler Shaham's NVCR Position: Q2 2021 in Review

Altshuler Shaham sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 743 shares — an estimated $98K sold.

Altshuler Shaham first reported a position in NVCR in Q3 2018 and held it in 7 quarters. The position peaked at $639K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Altshuler Shaham reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Altshuler Shaham sold 743 NovoCure shares in Q2 2021, an estimated $98K.
  • Altshuler Shaham first reported a position in NovoCure in Q3 2018 and held it in 7 quarters.
  • Altshuler Shaham's NovoCure position peaked at $639K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Altshuler Shaham's 13F filing for Q2 2021, filed 16 Aug 2021.